2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5265 Genomic determinants of early progression after CD19 CAR T-cell therapy in large B-cell lymphoma

Silvia Escribano Serrat, MD, Sandeep Sunder Raj, MD2, Aaron Gillmor, PhD3, Sigrun Einarsdottir, MD, PhD4, Marina Gomez-Llobell, MD5, Evgeniia Alekseeva6, Nazar Arutyunyan7, Alexander Nesmelov8, Andrey Suponin9, Pavel Zemskiy10, Dmitrii Snitkin11, Gunjan L. Shah, MD, MS12, Maria Lia Palomba, MD13, Michael Scordo, MD14, Connie Batlevi, MD15, Craig Sauter, MD16, Jae H Park, MD17, Kai Rejeski, MD18, Miguel-Angel Perales, MD19, Marcel R.M. van den Brink Jr, M.D., Ph.D.20, Gilles Salles I, MD, PhD21, Roni Shouval Jr, MD, PhD22
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Universitat Autònoma de Barcelona, Barcelona, Cataluña, Spain
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New york, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Complutense University of Madrid, Madrid, Madrid, Spain, Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 BostonGene Corporation, Waltham, Massachusetts, United States
7 BostonGene Corporation, Waltham, Massachusetts, United States
8 BostonGene Corporation, Waltham, Massachusetts, United States
9 BostonGene Corporation, Waltham, Massachusetts, United States
10 BostonGene Corporation, Waltham, Massachusetts, United States
11 BostonGene Corporation, Waltham, Massachusetts, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
18 LMU University Hospital, Munich, Germany, Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
20 City of Hope National Medical Center, Duarte, California, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
Background: Clinical risk factors incompletely explain the marked heterogeneity in outcomes after CD19-directed chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL). We sought to define the pre-CAR-T tumor genomic landscape and identify molecular features associated with early treatment failure.

Methods: We retrospectively studied patients with relapsed/refractory LBCL treated who received commercial CAR T-cell therapy during 2016–2022 and had an available pre-CAR-T tumor specimen. Whole-exome sequencing (WES) was analyzed using a standardized pipeline. Cell of origin (COO) was assigned by Hans algorithm; double-hit/triple-hit lymphoma (DHIT) and MYC rearrangement by FISH; and double-expressor status by MYC ≥40% and BCL2 ≥50% expression. Somatic mutations, oncogenic pathways, and mutational signatures were evaluated across clinicopathologic subgroups. Genomic subtypes were assigned using the established LymphGen framework and Lymphly (Snitkin et al, Blood, 2025). Primary outcome was progression or death within 6 months of CAR T-cell infusion (PFS6 event). Associations were assessed using Fisher exact tests and logistic regression. Multiplicity was controlled using the Benjamini–Hochberg method where applicable; groups with <10 patients were excluded from comparative analyses.

Results: Pre-CAR-T WES was available for 99 patients. Histologies included DLBCL NOS (75%), high-grade B-cell lymphoma (20%), and other LBCL subtypes (5%). Overall, 35% of tumors represented transformed lymphoma, 41% of patients had primary refractory disease, 46% had received ≥3 prior lines of therapy, and 26% had undergone prior auto-HCT. Median follow-up was 61.2 months (IQR, 43.5–76.6). Products included axi-cel (54%), tisa-cel (35%), and liso-cel (11%). Among evaluable tumors, 50% were GCB, 18% were DHIT, 47% were double expressors, and 26% harbored a MYC rearrangement.

The most frequently mutated genes were KMT2D (35%), TP53 (32%), BCL2 (26%), CREBBP (25%), PIM1 (22%), and MYD88 (21%). BCL2 mutations were enriched in GCB tumors (46% vs 8%; FDR<0.001) and DHIT (71% vs 18%; FDR<0.001). TNFRSF14 was mutated in 16% of tumors, enriched in DHIT (41% vs 11%; FDR=0.03), and associated with numerically lower odds of early progression or death (OR, 0.31; P=0.058). TP53 mutation was not associated with a PFS6 event.

The most commonly altered pathways were NOTCH (66%), Hippo (49%), RTK–RAS (49%), TP53 (34%), and WNT (33%). PI3K pathway alterations occurred in 26% of tumors, were enriched in GCB disease (41% vs 9%; FDR<0.001), and were associated with early progression or death (OR, 3.78; P=0.009). This association remained significant in models individually adjusted for COO, DHIT, double-expressor status, or MYC rearrangement (all P≤0.013).

The predominant mutational signatures were defective DNA mismatch repair (92%), spontaneous deamination (87%), and double-strand break repair failure (57%); none was associated with early progression or death.

Lymphly assigned genomic subtypes to a larger proportion of evaluable cases than LymphGen and demonstrated improved outcome discrimination. Major Lymphly subtypes were EZB (34%), MCD (23%), BN2 (21%), and JS6 (10%). Subtype distribution differed by COO and DHIT status (both FDR<0.001), with MCD enriched among non-GCB tumors and EZB among both GCB and DHIT tumors. Genomic features also differed across subtypes: BCL2, CREBBP, and TNFRSF14 mutations were most frequent in EZB, MYD88 mutations in MCD, and B2M and SOCS1 mutations in JS6 (all FDR<0.05). PFS6 events occurred in 29% of patients with EZB, 39% with MCD, 50% with JS6, and 76% with BN2. Compared with EZB, BN2 was strongly associated with a PFS6 event (OR, 7.68;  P=0.001). After adjustment for pre-lymphodepletion LDH, BN2 remained independently associated with early progression or death (OR, 21.60; overall P<0.001).

Conclusions: Pre-CAR-T LBCL is genomically heterogeneous, and conventional high-grade molecular features incompletely capture clinically relevant biology. PI3K pathway alterations and the Lymphly BN2 subtype identified tumors at high risk of progression within 6 months, whereas TNFRSF14 mutation and Lymphly EZB subtype may mark a more favorable subgroup. These findings suggest that pre-CAR-T tumor genomic profiling could improve identification of patients at high risk for early treatment failure beyond conventional clinicopathological features.
Silvia Escribano Serrat, MD: Alfonso Martín Escudero Foundation - Research Funding; Alfonso Martín Escudero Foundation - Research Funding